MDS Virtual Congress 2020 » Parkinson’s Disease: Clinical Trials

A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes

A. Thach, J. Sutphin, J. Coulter, C. Mansfield (Marlborough, MA, USA)

A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in De Novo vs Rollover Patients With Parkinson’s Disease: Interim Results

R. Pahwa, S. Fox, C. Singer, P. Bhargava, B. Navia (Kansas City, KS, USA)

A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Interim Results

S. Factor, W. Ondo, S. Isaacson, P. Bhargava, B. Navia (Atlanta, GA, USA)

A Patient with Gait Disturbance Caused by Parkinson’s Disease: A Case Report

M. Park, SS. Park, S.H Lee, C.Y Kim, I.W Choi, I.C Chae, H.R Yoo (Daejeon, Republic of Korea)

A pooled analysis of four pivotal, randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: Efficacy as adjunct to levodopa in Parkinson’s disease (PD)

C. Waters, R. Hauser, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (New York, NY, USA)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)

E. Rawner, J. Powell, S. Minami, K. Tang, V. Klutzaritz, E. McCaskill Newman, J. Hannestad (San Carlos, CA, USA)

A retrospective analysis of multicenter brain signal data recorded in Parkinson’s subjects implanted with deep brain stimulation leads

M. Case, H. Bronte-Stewart, A. Kuhn, K. Botzel, A. Hebb, P. Starr, B. Klassen, N. Ince, Z. Blumenfeld, J. Neumann, F. Hell, S. Hanrahan, N. Swann, M. Ozturk, S. Stanslaski, S. Goetz, T. Denison, K. Bhatia, R. Raike (Fridley, MN, USA)

A video self-modelling virtual reality intervention for freezing of gait in Parkinson’s disease: Preliminary findings from a pilot trial

L. Goh, N. Ahmadpour, N. Allen, L. Clemson, E. Gorgon, S. Lewis, H. MacDougall, K. Ehgoetz Martens, J. Song, C. Canning (Lidcombe, Australia)

AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease

S. Factor, A. Van Laar, R. Richardson, C. Christine, P. Larson, S. Kostyk, R. Lonser, C. Li, G. Liang, A. Meier, E. Fine, R. Gross (Atlanta, GA, USA)

Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease: ADAPT-PD Trial: A Prospective Single-Blind, Randomized Crossover, Multi-Center Trial of Deep Brain Stimulation Adaptive Algorithms in Subjects with Parkinson’s Disease

A. Kuhn, L. Tonder, R. Raike, S. Stanslaski, K. Lynch, H. Bronte-Stewart (Berlin, Germany)

Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease

M. Schiess, J. Suescun, M. Doursout, C. Adams, C. Green, J. Saltarrelli, S. Savitz, T. Ellmore (Houston, TX, USA)

Ambulosono: A Novel Sensor-based System for Quantitative Evaluation Freezing of Gait in Parkinson’s disease

W. Xian, B. Hu, L. Chen, Z. Pei (Guangzhou, China)

Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials

R.A Hauser, D. Chernick, A. Formella (Tampa, FL, USA)

Ampreloxetine (TD-9855), a long-acting, norepinephrine reuptake inhibitor (NRI) for the treatment of neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies: Phase 3 clinical program

L. Norcliffe-Kaufmann, C. Shibao, I. Biaggioni, H. Kaufmann, W. Wang, R. Vickery, B. Haumann (New York, NY, USA)

Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains

M. Siddiqui, V. Evidente, P. Bhargava, B. Navia, E. Pappert (Winston-Salem, NC, USA)

Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact of Concomitant Antiemetics and Dopamine Agonists on Nausea and Vomiting

A. Ellenbogen, A. Nicholas, R. Hauser, P. Bhargava, E. Pappert, B. Navia (Farmington Hills, MI, USA)

Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Dyskinesia

K. Klos, J. Hui, B. Robottom, P. Bhargava, B. Navia (Tulsa, OK, USA)

Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders

A. Espay, K. Markopoulou, P. Bhargava, B. Navia (Cincinnati, OH, USA)

Application of PKG System for Objective Measurement and Early Identification in Parkinson’s Disease

C. Lina, C. Guoen, W. Huidan, W. Yingqing, C. Ying, C. Xiaochun, Y. Qinyong (Fuzhou, China)

Are effects of Rock Steady Boxing and PD SAFExTM on the motor symptoms of Parkinson’s disease maintained long-term? – A single-blinded randomized controlled trial

K. Sangarapillai, B. Norman, Q. Almeida (Waterloo, ON, Canada)

Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics

M. Facheris, J. Streit, J. Jia, D. Standaert (North Chicago, IL, USA)

Baseline results of a virtual longitudinal, observational study of Parkinson’s disease: The AT-HOME PD cohort

T. Myers, R. Schneider, L. Omberg, E. Macklin, E. Baloga, P. Snyder, S. Duquette, K. Amodeo, C. Tarolli, J. Adams, C. Lungu, J. Gottesman, E. Kayson, E. Dorsey, L. Mangravite, T. Simuni, M. Schwarzschild (Boston, MA, USA)

Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson´s Disease with Cognitive Impairment: A Safety and Feasibility Study

C. Gasca-Salas, J. Pineda-Pardo, B. Fernández-Rodríguez, R. Rodríguez-Rojas, F. Hernández, I. Obeso, M. del Álamo, P. Guida, D. Mata-Marin, R. Martínez-Fernández, C. Ordás-Bandera, G. Foffani, I. Rachmilevitch, J. Obeso (Móstoles, Spain)

Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes

A. Thach, N. Kirson, M. Zichlin, I. Dieye, E. Pappert, G. Williams (Marlborough, MA, USA)

Cardiovascular Fitness, Plasma Biomarkers and Dopaminergic Denervation in Parkinson’s Disease

J. Morley, J. Dubroff, G. Cheng, B. Taylor, S. Wood, J. Duda (Philadelphia, PA, USA)

CHIEF-PD: Cholinesterase Inhibitor to prEvent Falls in Parkinson’s Disease

S. Neumann, J. Taylor, A. Bamford, C. Metcalfe, D.M Gaunt, A. Whone, D. Steeds, S.R Emmett, W. Hollingworth, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

Clinical Implication of Stimulus Induced Dyskinesia in Pallidal Deep Brain Stimulation for Advanced Parkinson’s Disease

S.H Lee, K.W Park, S.Y Jo, Y.S Hwang, M.S Kim, S.R Jeon, S.J Chung (Seoul, Republic of Korea)

Clinical research of serum uric acid levels in Parkinson’s disease

J.W Wu, T. Wang (Wuhan, China)

Comparative evaluation of the biomechanical analysis of gait in patients with Parkinson’s disease vs controls of the Zambrano Hellion Hospital

L.z Alvarado, H. Martínez, A. Sarreon, L. Guerrero, C. Cámara (SPGG, Mexico)

Comparison of Categorical- and Verbatim-Reported Postural Instability Symptoms Among Fox Insight Parkinson Research Participants

M. Javidnia, L. Arbatti, A. Hosamath, S. Eberly, D. Oakes, A. Nguyen, I. Shoulson (Rochester, NY, USA)

Comparison of gait measures in a clinic and a community setting in people with and without Parkinson’s disease

V. Shah, J. McNames, M. Mancini, P. Carlson-Kuhta, J. Nutt, M. El Gohary, C. Curtze, F. Horak (Portland, OR, USA)

CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks

A. Ellenbogen, A. Corbin, P. Zhao, D. Kegler-Ebo, H. Roberts (Bingham Farms, MI, USA)

Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study

S. Stodtmann, M. Rosebraugh, W. Robieson, M. Facheris (North Chicago, IL, USA)

Deep Brain Stimulation impact on Social and Occupational Function in Parkinson’s Disease with Early Motor Complications

V. Stoker, P. Krack, L. Tonder, A. Schnitzler, J.L Houeto, J. Rau, C. Schade-Brittinger, M. Vidailhet, G. Deuschl (Minneapolis, MN, USA)

Determination of non-motor symptoms in Parkinson’s disease in Kazakhstan (on the example of the city of Almaty)

A. Aralbayeva, A. Kondybaeva, S. Kamenova, K. Kuzhibaeva (Almaty, Kazakhstan)

Directional versus Omnidirectional Deep Brain Stimulation: Results of a Multicenter Prospective Blinded Crossover Study

A. Schnitzler, P. Mir, M.A Brodsky, L. Verhagen, S. Groppa, R. Alvarez, A. Evans, M. Blazquez, S. Nagel, W. Libionka, J. Pilitsis, M. Pötter-Nerger, W. Tse, L. Almeida, N. Tomycz, J. Jimenez-Shahed, F. Carrillo, C.J Hartmann, S.J Groiss, F. Defresne, E. Karst, B. Cheeran, J. Vesper (Plano, TX, USA)

Donepezil for mild cognitive impairment in Parkinson’s disease: A 48-week follow-up study

K. Baik, S. Kim, S. Kang, Y. Sohn, P. Lee, S. Kang (Seoul, Republic of Korea)

Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings

F. Stocchi, C. Olanow, E. Peckham, F. Agbo, Y. Chiu, K. Sciarappa, B. Navia (Rome, Italy)

Effect of Combined Modality Treatment on Sustained Phonation in Parkinson’s Disease

M. Cannito, N. Roussel, J. Tetnowski, K. Schiller, M. LeDoux, E. Buder, C. Royal-Evans, S. Narayana (Lafayette, LA, USA)

Effect of home-based functional training program on enhancing gross and fine upper extremity function in people with Parkinson’s disease – a randomized controlled trial

M.Y Mak, L.J Ren, I.K Wong-Yu (Hong Kong SAR, China)

Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial

X.D Yang, X.Q He, S.Q Xu, VV. Qian, Y. Zhang, YY. Song, Q. Xiao (Shanghai, China)

Effect of Levodopa-Carbidopa Intestinal Gel Versus Optimized Medical Treatment on Dyskinesia in Advanced Parkinson’s Disease Patients: Final Results of the Randomized 12-Week DYSCOVER Study

E.F Alvarez, C. Spanaki, E. Pekkonen, L. Manzanares, Y. Liu, O. Sánchez-Soliño, L. Barbato (Elche, Spain)

Effects of multimodal balance training supported by rhythmical auditory stimuli in people with advanced stages of Parkinson’s disease: A randomized clinical trial

T. Capato, J. Nonnekes, N. de Vries, J. IntHout, E. Barbosa, B. Bloem (São Paulo, Brazil)

Effects of Nabilone on non-motor symptoms of Parkinson´s Disease: A randomised placebo-controlled study (The NMS-Nab Study)

M. Peball, F. Krismer, H.G Knaus, A. Djamshidian, M. Werkmann, F. Carbone, P. Ellmerer, B. Heim, K. Marini, D. Valent, G. Goebel, H. Ulmer, H. Stockner, G.K Wenning, R. Stolz, K. Krejcy, W. Poewe, K. Seppi (Innsbruck, Austria)

Effects of Rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) Emotional Well-being Domain in Patients with Parkinson’s Disease (PD): A Post-Hoc Analysis of Clinical Trials in Japan

N. Hattori, A. Takeda, Y. Hanya, T. Kitagawa, M. Arai, Y. Furusawa, H. Mochizuki, M. Nagai, R. Takahashi (Tokyo, Japan)

Enhancement of executive functions but not memory by multidomain cognitive group training in Parkinson patients with mild cognitive impairment: A multicenter randomized controlled trial

E. Kalbe, A.K Folkerts, A. Ophey, C. Eggers, S. Elben, K. Dimenshteyn, P. Sulzer, C. Schulte, N. Schmidt, C. Schlenstedt, D. Berg, K. Witt, L. Wojtecki, I. Liepelt-Scarfone (Cologne, Germany)

Helicobacter pylori eradication in Parkinson’s disease: A double-blind randomized placebo-controlled study

A.H Tan, S.Y Lim, S. Mahadeva, M.F Loke, J.S Vadivelu, C. Marras, S.H Fox, A.E Lang (Kuala Lumpur, Malaysia)

Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study

S. Isaacson, T. Clinch, E. Farbman, R. Pahwa (Boca Raton, FL, USA)

Improvement for Gait Disorders in Parkinson’s Disease Through Novel Comprehensive Treatment (IMPROVE study): A Prospective, Open-label, Randomized Controlled Clinical Trial

X. Huang, L. Chen, G. Cai, J. Xin, Y. Yang, Q. Ye (Fuzhou, China)

Improving automaticity of walking in Parkinson’s disease: Levodopa or Donepezil?

S. Stuart, R. Morris, A. Giritharan, J. Quinn, J. Nutt, M. Mancini (Newcastle upon Tyne, United Kingdom)

In vivo imaging of presynaptic terminal loss in early Parkinson’s disease

A. Delva, D. Van Weehaeghe, M. Koole, K. Van Laere, W. Vandenberghe (Leuven, Belgium)

IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: A real-life study

B. Bergmans, V. Schotte, N. Sys, E. Van Massenhove, M. Van Zandijcke (Brugge, Belgium)

Interpretation of health-related quality of life outcomes from the EARLYSTIM Study

P. Martinez-Martin, G. Deuschl, L. Tonder, A. Schnitzler, J.L Houeto, J. Rau, C. Schade-Brittinger, V. Stoker, M. Vidailhet, P. Krack (Madrid, Spain)

Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study

S. Isaacson, W. Poewe, T. Simuni, O. Rosenfeld, R. Case, T. Yardeni, W. Olanow (Boca Raton, FL, USA)

Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

C. Tanner, D. Chernick, A. Formella (San Francisco, CA, USA)

Longitudinal clinical and imaging characteristics of non-manifest LRRK2 carriers: The PPMI cohort

T. Simuni, A. Siderowf, M. Brumm, C. Caspell, H. Cho, C. Coffey, T. Foroud, B. Mollenhauer, C. Tanner, K. Kieburtz, L. Chahine, K. Marek, p. PPMI Investigators (Chicago, IL, USA)

Morphological changes of retina in patients with Parkinson’s disease and the role of α-synuclein in retinal damage

L. Man, Z. Wei (Chengdu, China)

MOve To ImprovE physical activity in Parkinson’s disease (MOTIvatE): A pilot randomized clinical trial of gamification

N. Dahodwala, M. Engeland, W. Kerr, L. Walsh, M. Patel (Philadelphia, PA, USA)

NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson’s Disease: Exploratory Efficacy Outcomes

T. Simuni, C. Coffey, E. Klingner, C. Caspell-Garcia, D.E Lafontant, K. Merchant, B. Fiske, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, L. Baker, M. Kostrzebski, C. Venuto, G. Rafaloff, T. Ward (Chicago, IL, USA)

On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups

A. Thach, J. Coulter, C. Leach, J. Sutphin, C. Mansfield (Marlborough, MA, USA)

Open data sharing of the Parkinson’s Outcomes Project: A global, longitudinal clinical study of over 13,000 people with Parkinson’s disease

C. Marras, A. Naito, N. Dahodwala, A. Ramirez-Zamora, M. Rafferty, M. Neault, S. Wu, J. Beck, R. DeLeon, T. Davis (Miami, FL, USA)

Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics

M.J Peterschmitt, T. Gurevich, T. Gasser, H. Saiki, S. Isaacson, C. Waters, A.M Wills, S. Hassin-Baer, T. Simuni, N. Hattori, S. Gaemers, S.P Sardi, S. Saubadu, P. Minini, T. Fischer (Cambridge, MA, USA)

Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts

K. Marek, A. Siderowf, T. Simuni, C. Tanner (New Haven, CT, USA)

PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results

G. Pagano, K. Taylor, J. Cabrera, M. Marchesi, W. Zago, R. Tripuraneni, A. Boulay, A. Vogt, F. Boess, T. Nikolcheva, H. Svoboda, M. Britschgi, F. Lipsmeier, M. Lindemann, S. Dziadek, J. Azulay, B. Mollenhauer, L. Manzanares, D. Russell, J. Boyd, A. Nicholas, M. Luquin, R. Hauser, T. Simuni, T. Gasser, W. Poewe, G. Kinney, R. Doody, P. Fontoura, D. Umbricht, A. Bonni (Basel, Switzerland)

Passive monitored daily motor behavior significantly relates to quality of life in early Parkinson’s disease

A. Thomann, K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, R. Postuma, W.Y Cheng, B. van Lier, D. Trundell, W. Zago, A. Boulay, G. Pagano, C. Gossens, M. Lindemann (Basel, Switzerland)

Perspectives on care for late stage Parkinson’s disease

K. Rosqvist, M. Kylberg, C. Löfqvist, A. Schrag, P. Odin, S. Iwarsson (Lund, Sweden)

Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease

K. Merchant, T. Simuni, B. Fiske, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff, C. Venuto (Chicago, IL, USA)

Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease

J. Shirvan (Cambridge, MA, USA)

Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period

V. Kerstens, P. Fazio, J. Johansson, T. Granberg, S. Booms, H. Huttunen, M. Sjögren, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, G. Lind, P. Almqvist, F. Scheperjans, H. Widner, P. Svenningsson, J. Rinne, A. Varrone (Stockholm, Sweden)

Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period

H. Huttunen, S. Booms, H. Abdesselem, N. Majbour, O. El-Agnaf, I. Poggiolini, L. Parkkinen, A. Cryar, E. Sirka, J. Harris, M. Dove, M. Sjögren, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, P. Almqvist, P. Almqvist, G. Lind, F. Scheperjans, H. Widner, P. Svenningsson (Espoo, Finland)

Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study

S. Booms, H. Huttunen, J. Koskinen, M. Sjögren, M. Saarma, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, J. Rinne, A. Varrone, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, G. Lind, P. Almqvist, F. Scheperjans, H. Widner, P. Svenningsson (Espoo, Finland)

Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy

T. Birnberg, G. Smania, M. Bjornsson, N. Jonsson, R. Case, S. Oren, L. Adar, M. Karlsson (Rehovot, Israel)

Postmenopausal hormone therapy and Alzheimer’s disease, dementia, and Parkinson’s disease: A systematic review and time-response meta-analysis

M. wu, M. Ye (Nanjing, China)

Prevalence and Characteristics of Postural Deformities in Thai Patients with Parkinson’s Disease

T. Wangthumrong, C. Pongmala, Y. Pitakpatapee, J. Srikajon, M. Vichutavate, P. Srivanitchpoom (Bangkok, Thailand)

Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease

M. Geva, A. McGarry, Y. Cohen, T. Johnston, M. de Somer, K. Kieburtz, M. Hayden, J. Brotchie, C. Olanow (Herzliya, Israel)

Prospective assessment of the lessebo effect in placebo-controlled randomized trials using an expectancy questionnaire

T. Mestre, E. Macklin, C. Coffey, M. Kostrzebski, A. Ascherio, J. Ferreira, M. Schwarzschild, T. Simuni, A. Lang (Ottawa, ON, Canada)

Quantifying movement to measure Parkinson’s Disease severity and progression in a Phase 2 Study (SPARK)

K.P Kilambi, S. Khan, J. Osik, T. Herrero, J. Edgerton, K. Erb, K. Hallock, M. Brys, M. Yang, J. Xiao, I. Sapir, T. Fox, P. Bergethon (Cambridge, MA, USA)

Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients

E. Thijssen, J. den Heijer, D. Puibert, M. Lei, D. Hasegawa, K. Keum, K. Mochel, P. Roset, E. van Brummelen, T. Naranda, G. Groeneveld (Leiden, Netherlands)

Rapid on-time onset and sustained improvements in motor states throughout the day following treatment with levodopa/carbidopa intestinal gel (LCIG) vs immediate-release levodopa/carbidopa oral capsules (LCIR)

R. Pahwa, J. Aldred, N. Gupta, E. Terasawa, V. Garcia Horton, D. Macaulay, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, S. Isaacson (Kansas City, KS, USA)

Real Time Quality Control for Subjective Endpoints in Clinical Trials

Y. Peng, G. Morinan, J. O'Keeffe (London, United Kingdom)

Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study

S. Isaacson, A. Espay, R. Pahwa, T. Clinch, P. LeWitt (Boca Raton, FL, USA)

Remote video-based research visits in a phase 3 clinical trial in Parkinson’s disease

C. Tarolli, K. Andrzejewski, G. Zimmerman, M. Bull, S. Goldenthal, P. Auinger, E.R Dorsey, K. Biglan, T. Simuni (Rochester, NY, USA)

Researches on the correlation between wearable device data and UPDRS scores in patients with Parkinson’s disease

B.o Shen (Nanjing, China)

Resistance Training on Postural Control in Parkinson’s Disease: a Randomized Controlled Trial

C. Souza, J. Chen, D. Francato, A. Barbosa, M. Voos, E. Barbosa, H. Chien (Sao Paulo, Brazil)

Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies

L. Elmer, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (Toledo, OH, USA)

Safety and Tolerability of Burst Cycling Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease

W. Hu, J. Wang, R. Barmore, J. Melo Lobo, T. Tsuboi, A. Wang, A. Ramirez-Zamora, M. Okun, L. Almeida (Gainesville, FL, USA)

Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations

D. Jennings, P. LeWitt, D. Kern, I. Goodman, A. Siderowf, O. Omidvar, A. Ellenbogen, J. Aldred, R. Macuica, S. Huntwork-Rodriguez, C. Ho, M. Troyer (South San Francisco, CA, USA)

Serious games home rehabilitation program to treat gait and balance disorders in patients with Parkinson’s disease: A randomised controlled trial

D. Nuic, S. de Weijer, E. Zeeboer, C. Olivier, S. Cherif, P. Foulon, B.R Bloem, N. De Vries, M.L Welter (Paris, France)

Serum microRNA expression levels in Turkish patients with Parkinson’s disease

B. Ozdilek, B. Demircan (Istanbul, Turkey)

Severity of Motor Symptoms in Parkinson’s Disease in Kazakhstan (on the example of the city of Almaty)

A. Aralbayeva, S. Kamenova, A. Kondybaeva, K. Kuzhibaeva (Almaty, Kazakhstan)

Site investigator perspectives on exclusionary determinations of SWEDDs (Scans Without Evidence of Dopaminergic Deficit) during screening in the SURE-PD3 study

G. Crotty, E. Macklin, A. Hung, M. Schwarzschild (Boston, MA, USA)

The Association of Taichi to Delayed Progression of Parkinson’s Disease

P. Huang, G. Li, Y.C He, S.D Chen (Shanghai, China)

The Cognitive Training In Parkinson Study (COGTIPS), a randomized controlled trial

T. van Balkom, H. Berendse, Y. v.d. Werf, J. Twisk, R. Hagen, T. Berk, O. v.d. Heuvel, C. Vriend (Amsterdam, Netherlands)

The exosomal a-syn filaments can be a novel biomarker of Parkinson’s disease

Y. Ishiguro, T. Tsunemi, A. Yoroisaka, N. Hattori (Tokyo, Japan)

The Levodopa in Early Parkinson’s disease (LEAP) study: Post-hoc analyses

H. Frequin, J. Schouten, R. de Bie, L. LEAP-study group (Amsterdam, Netherlands)

The Personalized Parkinson Project – data quality enhancing strategies

B. Bloem, L. Evers, T. vande Zande, R. Kapur, M. Meinders, W. Marks, Jr (Nijmegen, Netherlands)

The UP study – Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson’s disease

T. Payne, M. Appleby, E. Buckley, C. Mazza, T. Foltynie, O. Bandmann (Sheffield, United Kingdom)

Therapeutic Benefits of Music for Three Types of Neurological Disorders: an fNIRS Study Protocol for Controlled Trial in Dalian, China, Part 1-Parkinson’s Disease

LL. Pu, Z.H Liang, W.C Tang, F.Y Cong, B.W Zhang, N.K Qureshi, J. Ly, T. Li (Dalian, China)

Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease

C. Christine, R. Richardson, A. Van Laar, M. Thompson, K. Herbert, C. Li, G. Liang, E. Fine, P. Larson (San Francisco, CA, USA)

Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson’s disease (PD)

J.R Menezes, R.B Carra, G.A Nunes, J.S Simões, M.J Teixeira, K.P Duarte, D.C Andrade, E.R Barbosa, M.A Marcolin, R.G Cury (São Paulo, Brazil)

Types of Pain in Parkinson`s Disease Patients

I. Petrov (Skopje, The former Yugoslav Republic of Macedonia)

Using a Delphi process to inform the design of disease modifying trials in Parkinson’s disease

M. Zeissler, R. Windle, K. McFarthing, K. Raphael, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

Using mindfulness to improve self-awareness in Parkinson’s disease patients – preliminary results of a randomized controlled trial

T. Buchwitz, F. Maier, A. Greuel, C. Eggers (Marburg, Germany)

Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson’s Disease

D. Hall, S. Kapur, C. Vaughan, J. Hawkins, G. Stebbins (Chicago, IL, USA)

WATCH-PD: Wearable Assessments in the Clinic and Home in Parkinson’s Disease: Study Design and Update

J.L Adams, E.R Dorsey, A. Steinman, T. Kangarloo, R. Alexander, B. Tracey, N. Zach, R. Rubens, M. Kostrzebski, M. Bockus, R. O'Loughlin, E.A Stevenson, J. Cosman (Rochester, NY, USA)